Global Ion-Pair Reagents Market Outlook, 2031

Ion-pair reagents are small in volume but outsized in strategic importance, because they make it possible to separate the charged and highly polar molecules that ordinary reversed-phase chromatography cannot retain. By pairing a hydrophobic tail with a charged head group, compounds such as alkyl sulphonates, tetraalkylammonium salts, perfluorinated acids like trifluoroacetic acid and alkylamines such as triethylamine and hexylamine form neutral complexes with analytes, typically at concentrations of 5 to 100 millimolar in the mobile phase. The technique, developed in the 1970s, is written into many pharmacopoeial methods for ionic drugs, vitamins and nucleotides, and in the 1990s the combination of triethylamine with hexafluoroisopropanol made ion-pair LC-MS of oligonucleotides practical. Alkyl sulphonates, perfluorinated carboxylic acids and alkylamine and HFIP systems each account for roughly a quarter of reagent use, tetraalkylammonium salts about 20% and other reagents the remainder. Pharmaceutical and biotechnology companies and CDMOs consume around 70% of supply, academic and research laboratories about 15% and testing and industrial users the rest. Suppliers include Merck KGaA, Thermo Fisher, Avantor, Honeywell, Tokyo Chemical Industry, Fujifilm Wako, Waters, Agilent, Regis Technologies, Carl Roth and specialised oligonucleotide-reagent producers, and North America accounts for about 38% of demand, Europe about 30% and Asia-Pacific about 27%.

The growth story is written by oligonucleotide and peptide therapeutics. Ion-pair reversed-phase chromatography with alkylamines and hexafluoroisopropanol is the standard method for analysing and purifying antisense and siRNA drugs, and the approvals of Alnylam's Amvuttra for transthyretin amyloid cardiomyopathy and Sanofi's Qfitlia in March 2025 and Arrowhead's Redemplo in November 2025, together with Novartis's agreement in October 2025 to acquire Avidity Biosciences, signal a rapidly expanding production base for a drug class that numbered only a handful of approved products before 2018. GLP-1 peptide manufacturing, which uses trifluoroacetic acid at typical concentrations of around 0.1% in analysis and purification, has scaled dramatically since 2023. As a result, alkylamine and HFIP systems are growing at an estimated 12% to 14% a year and are expected to exceed a third of reagent use by 2031. Key watch points include LC-MS compatibility, since non-volatile reagents can contaminate mass spectrometers and permanently modify columns, supply concentration for ultra-pure amines and HFIP, which is produced by only a few manufacturers, and the EU's proposed universal PFAS restriction, published in 2023, which could affect TFA and other perfluorinated ion-pair agents unless analytical uses are exempted.

Drivers Growth of Oligonucleotide and Peptide Therapeutics Antisense and siRNA drugs, mRNA, aptamers and peptide drugs including GLP-1 agonists require ion-pair chromatography for analysis, impurity profiling and purification, and approvals such as Amvuttra for cardiomyopathy, Redemplo and Qfitlia in 2025, together with expanding pipelines and manufacturing capacity, increase demand for specialised ion-pair reagents such as alkylamines, HFIP and TFA.
Analysis of Polar and Ionic Compounds Ion-pair chromatography remains important for analysing polar and ionic compounds, including many small molecule drugs, vitamins, amino acids, nucleotides, metabolites, surfactants and environmental contaminants, in pharmaceutical quality control, food analysis, clinical testing and research. Pharmacopoeial methods specify ion-pair reagents for many drug assays, sustaining demand.

Challenges LC-MS Compatibility and Alternative Techniques Many traditional ion-pair reagents, such as alkyl sulphonates and tetraalkylammonium salts, are non-volatile and incompatible with mass spectrometry, and they can permanently modify columns. Alternative techniques, including hydrophilic interaction liquid chromatography, mixed-mode chromatography and ion chromatography, compete for some applications, limiting growth of traditional reagents.
Purity Requirements, Supply Concentration and PFAS Scrutiny Oligonucleotide and LC-MS applications require reagents with very low metal and impurity levels, and few suppliers produce high-purity amines and HFIP, creating supply risks. Perfluorinated ion-pair agents such as TFA and HFBA may face scrutiny under proposed PFAS restrictions, potentially requiring alternatives. The niche scale of the category limits investment in new products.

Trends Oligonucleotide-Specific Ion-Pair Systems Suppliers are developing and qualifying high-purity alkylamine and HFIP reagents, ready-to-use mobile phases and optimised ion-pair systems for oligonucleotide analysis by LC-MS and purification at manufacturing scale, and instrument makers such as Waters and Agilent offer oligonucleotide-specific columns and methods. Alternatives to HFIP that reduce cost and toxicity are being explored.
MS-Compatible and Sustainable Reagents Laboratories are moving toward volatile, MS-compatible ion-pair reagents and lower concentrations to protect instruments, and suppliers offer LC-MS-grade reagents with certified low metal content. Interest in replacing perfluorinated reagents with non-PFAS alternatives and reducing hazardous reagent use is growing.



Alkyl sulphonates, perfluorinated carboxylic acids and alkylamine and HFIP systems each account for about a quarter of ion-pair reagent use because they serve distinct compound classes, from basic drugs to peptides to oligonucleotides, in widely used methods. Alkyl sulphonates, including sodium pentane-, hexane-, heptane-, octane- and dodecanesulphonate, account for about a quarter of ion-pair reagent use. They pair with protonated basic drugs, amines and catecholamines and are written into many pharmacopoeial monographs, ensuring steady demand from quality control laboratories even though they are non-volatile and unsuitable for mass spectrometry. Tetraalkylammonium salts, including tetrabutylammonium hydrogen sulphate, bromide, phosphate and hydroxide, account for around 20% of use, pairing with acidic compounds such as organic acids, sulphonates, nucleotides and some vitamins. Perfluorinated carboxylic acids, including trifluoroacetic acid, pentafluoropropionic acid and heptafluorobutyric acid, account for about 25%, used extensively in peptide and protein separations because they are volatile and sharpen peaks, although TFA suppresses electrospray ionisation and is often replaced by formic or difluoroacetic acid in LC-MS. Alkylamine and hexafluoroisopropanol systems, including triethylamine, hexylamine, dibutylamine, diisopropylethylamine and triethylammonium acetate combined with HFIP, account for around 25% and are the fastest-growing category because they enable high-resolution LC-MS analysis and purification of oligonucleotides. HFIP is expensive and supplied by few producers, making it a significant cost driver. Other reagents, including chiral ion-pair agents, ion-pair concentrates and specialty amines, made up the remainder. Volatility, purity, UV transparency and compatibility with column chemistries determine reagent selection. Difluoroacetic acid is gaining attention as a compromise between TFA's chromatographic performance and formic acid's MS compatibility. Concentration matters as well, since many methods use ion-pair reagents at 5 to 100 millimolar, and even small changes can shift retention significantly. Column dedication is common because some ion-pair reagents permanently modify stationary phases.

Oligonucleotide and peptide applications are the fastest-growing ion-pair reagent uses because expanding RNA and GLP-1 drug pipelines require ion-pair methods for analysis, impurity profiling and purification, while small molecule pharmaceutical analysis remains the largest established application. Small molecule pharmaceutical analysis accounts for an estimated 35% of ion-pair reagent demand, covering assays and impurity tests for ionic drugs under pharmacopoeial and validated methods, many of which date back decades and are costly to replace. Oligonucleotide analysis and purification accounts for around 30% of demand and is growing at 12% to 14% a year, covering antisense oligonucleotides, siRNA, aptamers, guide RNAs for gene editing and mRNA fragments, where ion-pair reversed-phase LC-MS characterises full-length products and failure sequences, and preparative ion-pair chromatography purifies material at scale. Peptide and protein analysis and purification accounts for about 20%, including GLP-1 agonists, insulin analogues and other peptide drugs, with TFA widely used in both analysis and purification. Food and beverage analysis accounts for around 5%, using ion-pair methods for water-soluble vitamins, preservatives, sweeteners and dyes. Clinical and biochemical analysis accounts for about 5%, covering catecholamines, nucleotides, organic acids and metabolites. Environmental and industrial analysis, including surfactants, ionic dyes and ionic contaminants, made up the remainder. Alternative techniques, including hydrophilic interaction liquid chromatography, mixed-mode chromatography and ion chromatography, compete in some applications, particularly for small polar molecules. The rapid expansion of oligonucleotide manufacturing capacity by CDMOs and drug developers is the single largest influence on future demand. Gene editing therapies, such as CRISPR-based medicines that require synthetic guide RNAs, add a further demand stream for oligonucleotide-grade ion-pair reagents. Each new oligonucleotide or peptide drug approval typically brings a family of validated methods into routine quality control, steadily expanding baseline demand.

HPLC-grade ion-pair reagents account for the largest share of volume because established pharmacopoeial methods rely on them, while LC-MS-grade and oligonucleotide-grade reagents are growing fastest as sensitivity requirements and RNA drug production increase. HPLC-grade ion-pair reagents account for an estimated 45% of volume, used mainly in UV-based quality control methods for small molecule drugs and foods, with specifications focused on UV absorbance and purity. LC-MS-grade reagents, with low metal ion content and minimal impurities that cause adducts or background signals, account for around 25% of use and are growing quickly as mass spectrometry replaces UV detection in many laboratories. Oligonucleotide-grade reagents, including high-purity triethylamine, hexylamine, dibutylamine and HFIP with tightly controlled water, metal and degradation product levels, account for about 20% of use and command significant price premiums, as impurities can affect separation of closely related oligonucleotide sequences and contaminate costly products. Bulk grades for preparative and process purification are supplied in drums and larger containers to CDMOs and drug manufacturers, and their volume is rising with oligonucleotide and peptide production. Ready-to-use concentrates and premixed ion-pair mobile phases simplify preparation, improve reproducibility and reduce exposure to hazardous amines and HFIP, accounting for a small but growing share. Packaging under inert gas, small single-use ampoules and amber bottles help preserve amine reagents, which can degrade and form impurities over time. Certificates of analysis and lot traceability are essential for GMP laboratories. Suppliers that can guarantee consistent quality at both analytical and production scales are increasingly favoured by oligonucleotide manufacturers. Some suppliers now offer application-tested reagent kits validated on specific column chemistries. Shelf life and storage conditions are especially important for amines, which can oxidise and form impurities that interfere with oligonucleotide separations. Some manufacturers require dual sourcing for critical oligonucleotide-grade reagents.

Pharmaceutical and biotechnology companies and CDMOs account for about 70% of ion-pair reagent demand because they run regulated analytical methods and large-scale purification of ionic drugs, peptides and oligonucleotides under strict quality requirements. Pharmaceutical and biotechnology companies account for an estimated 45% of ion-pair reagent demand, including oligonucleotide developers such as Alnylam, Ionis, Arrowhead and Novartis, peptide drug makers such as Novo Nordisk and Eli Lilly, and generic drug manufacturers in India, China and Europe running pharmacopoeial methods. Contract development and manufacturing organisations account for around 25%, including oligonucleotide specialists such as Agilent's nucleic acid manufacturing business, Nitto Avecia, WuXi STA and Ajinomoto Bio-Pharma, and peptide CDMOs such as Bachem, CordenPharma and PolyPeptide, which use ion-pair reagents in both analysis and preparative purification. Academic and research laboratories account for about 15%, using ion-pair methods in biochemistry, nucleic acid research and analytical method development. Testing laboratories in food, clinical, environmental and contract analytical fields account for around 10%. Chemical companies and other users made up the remainder. Purchasing patterns differ between quality control laboratories, which buy small quantities of HPLC-grade reagents through distributors, and oligonucleotide and peptide manufacturers, which negotiate supply agreements for high-purity bulk reagents and often qualify multiple sources to reduce risk. Large manufacturers are increasingly concerned about supply security for HFIP and specialty amines, given limited producers. Sustainability and worker safety considerations are prompting interest in lower-toxicity alternatives and solvent recycling. Regulatory filings that specify ion-pair methods effectively lock in reagent choices for the lifetime of a product, giving qualified suppliers long-term demand visibility. Universities and research institutes engaged in RNA therapeutics and gene editing research are also expanding consumption of oligonucleotide-grade ion-pair reagents. Government laboratories involved in pharmacopoeial standard setting form a small but influential user group.

North America accounts for about 38% of ion-pair reagent demand, Europe for about 30% and Asia-Pacific for around 27%, with Asia-Pacific growing fastest. North America accounts for about 38% of global demand, led by the United States, home to many oligonucleotide and peptide drug developers and CDMOs, including Alnylam, Ionis and Arrowhead, a large pharmaceutical quality control sector and suppliers such as Thermo Fisher, MilliporeSigma, Avantor, Waters and Agilent. Europe accounts for about 30%, with pharmaceutical and peptide manufacturing in Switzerland, Denmark, Germany and the UK, oligonucleotide CDMOs and suppliers such as Merck KGaA and Carl Roth, while the EU's proposed PFAS restriction could affect perfluorinated ion-pair agents. Asia-Pacific accounts for around 27% and is the fastest-growing region, with China's and India's pharmaceutical, peptide and oligonucleotide manufacturing, Japan's reagent suppliers such as Tokyo Chemical Industry and Fujifilm Wako, and growing CDMO capacity in China, India and South Korea. Latin America, the Middle East and Africa have small markets.

• 2025 – FDA approves Redemplo (plozasiran): Arrowhead's siRNA therapy was approved for familial chylomicronaemia syndrome, adding to the oligonucleotide drugs whose analysis and purification rely on ion-pair chromatography.
• 2025 – Novartis agrees to acquire Avidity Biosciences: Novartis agreed to buy Avidity for about USD 12 billion, expanding oligonucleotide-based therapeutic development and related analytical needs.
• 2025 – FDA approves Amvuttra for ATTR cardiomyopathy: Alnylam's siRNA vutrisiran was approved for a large heart failure population, increasing production of oligonucleotide drugs analysed with ion-pair methods.
• 2025 – FDA approves Qfitlia (fitusiran) for haemophilia: Sanofi's siRNA therapy was approved, adding to the growing number of oligonucleotide medicines.
• 2024 – GLP-1 peptide manufacturing capacity expands: Novo Nordisk, Eli Lilly and CDMOs invested heavily in peptide manufacturing, increasing use of TFA and other ion-pair reagents in analysis and purification.
• 2023 – EU publishes proposal for broad PFAS restriction: European authorities published a proposal to restrict PFAS, which could affect perfluorinated chemicals including some ion-pair reagents, subject to exemptions.

Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• Global Ion-Pair Reagents Market with its value and forecast along with its segments
• Various drivers and challenges
• Ongoing trends and developments
• Top profiled companies
• Strategic recommendation

By Reagent Type
• Alkyl Sulphonates
• Tetraalkylammonium Salts
• Perfluorinated Carboxylic Acids
• Alkylamines and HFIP Systems
• Other Ion-Pair Reagents

By Application
• Small Molecule Pharmaceutical Analysis
• Oligonucleotide Analysis and Purification
• Peptide and Protein Analysis
• Food and Beverage Analysis
• Clinical and Biochemical Analysis
• Environmental and Industrial Analysis

By Grade
• HPLC Grade
• LC-MS Grade
• Oligonucleotide Grade
• Bulk Grade
• Ready-to-Use Concentrates

By End User
• Pharmaceutical and Biotechnology Companies
• CDMOs
• Academic and Research Laboratories
• Testing Laboratories
• Chemical Companies